Статті в журналах з теми "Market exclusivity"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Market exclusivity".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Luchetti, Cynthia. "Market Exclusivity Strategies for Pharmaceuticals." Pharmaceutical Medicine 23, no. 2 (April 2009): 77–84. http://dx.doi.org/10.1007/bf03256753.
Повний текст джерелаDowning, Nicholas S. "Market Exclusivity for Top-Selling Pharmaceuticals." JAMA Internal Medicine 175, no. 4 (April 1, 2015): 637. http://dx.doi.org/10.1001/jamainternmed.2014.7972.
Повний текст джерелаGrootendorst, Paul, Minsup Shim, Adam Falconi, Tyler Robinson, and Joel Lexchin. "Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario." International Journal of Health Services 48, no. 4 (July 24, 2018): 702–15. http://dx.doi.org/10.1177/0020731418789610.
Повний текст джерелаDunn, Michael K. "Timing of patent filing and market exclusivity." Nature Reviews Drug Discovery 10, no. 7 (July 2011): 487–88. http://dx.doi.org/10.1038/nrd3494.
Повний текст джерелаGoldman, Dana P., Darius N. Lakdawalla, and Tomas J. Philipson. "Market Exclusivity For Drugs: The Authors Reply." Health Affairs 30, no. 4 (April 2011): 799. http://dx.doi.org/10.1377/hlthaff.2011.0308.
Повний текст джерелаArgenton, Cédric, and Bert Willems. "Exclusivity Contracts, Insurance and Financial Market Foreclosure." Journal of Industrial Economics 60, no. 4 (December 2012): 609–30. http://dx.doi.org/10.1111/joie.12000.
Повний текст джерелаKesselheim, Aaron S. "Adalimumab Pricing and Market Exclusivity for Biologics." New England Journal of Medicine 363, no. 24 (December 9, 2010): 2374. http://dx.doi.org/10.1056/nejmc1012150.
Повний текст джерелаChirieac Roxana Maria. "Considerations on exclusivity clauses." Technium Social Sciences Journal 14 (December 10, 2020): 286–92. http://dx.doi.org/10.47577/tssj.v14i1.2229.
Повний текст джерелаAshoori, Minoo, Eric Schmidbauer, and Axel Stock. "Exclusivity as a Signal of Quality in a Market with Word-of-Mouth Communication." Review of Marketing Science 18, no. 1 (August 19, 2020): 99–115. http://dx.doi.org/10.1515/roms-2020-0022.
Повний текст джерелаKesselheim, Aaron S. "Using Market-Exclusivity Incentives to Promote Pharmaceutical Innovation." New England Journal of Medicine 363, no. 19 (November 4, 2010): 1855–62. http://dx.doi.org/10.1056/nejmhle1002961.
Повний текст джерелаRagavan, Srividhya. "Data exclusivity: a tool to sustain market monopoly." Jindal Global Law Review 8, no. 2 (October 2017): 241–60. http://dx.doi.org/10.1007/s41020-017-0050-2.
Повний текст джерелаSheridan, Cormac. "EU to review rare disease drugs market exclusivity." Nature Biotechnology 22, no. 9 (August 27, 2004): 1061. http://dx.doi.org/10.1038/nbt0904-1061.
Повний текст джерелаGrabowski, Henry G., and Margaret Kyle. "Generic competition and market exclusivity periods in pharmaceuticals." Managerial and Decision Economics 28, no. 4-5 (2007): 491–502. http://dx.doi.org/10.1002/mde.1356.
Повний текст джерелаSon, Kyung-Bok, SeungJin Bae, and Tae-Jin Lee. "Does the Patent Linkage System Prolong Effective Market Exclusivity? Recent Evidence From the Korea-U.S. Free Trade Agreement in Korea." International Journal of Health Services 49, no. 2 (January 9, 2019): 306–21. http://dx.doi.org/10.1177/0020731418822237.
Повний текст джерелаMorag-Sela, Tamar, Ilan Cohn, Thomas J. Kowalski, Judy Jarecki-Black, and Zoe Clyde-Watson. "Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity." Nature Biotechnology 22, no. 12 (December 2004): 1591–92. http://dx.doi.org/10.1038/nbt1204-1591.
Повний текст джерелаLi, Xiaolu. "Analysis of the Exclusivity of Hermès Handbags." BCP Business & Management 21 (July 20, 2022): 294–99. http://dx.doi.org/10.54691/bcpbm.v21i.1253.
Повний текст джерелаRome, Benjamin N., and Aaron S. Kesselheim. "Transferrable Market Exclusivity Extensions to Promote Antibiotic Development: An Economic Analysis." Clinical Infectious Diseases 71, no. 7 (October 20, 2019): 1671–75. http://dx.doi.org/10.1093/cid/ciz1039.
Повний текст джерела&NA;. "New legislation could see orphan drug market exclusivity reduced." Inpharma Weekly &NA;, no. 932 (April 1994): 22. http://dx.doi.org/10.2165/00128413-199409320-00059.
Повний текст джерелаEngelberg, Alfred B., Aaron S. Kesselheim, and Jerry Avorn. "Balancing Innovation, Access, and Profits — Market Exclusivity for Biologics." New England Journal of Medicine 361, no. 20 (November 12, 2009): 1917–19. http://dx.doi.org/10.1056/nejmp0908496.
Повний текст джерелаMusselwhite, Laura, and Bryan Collingsworth. "Societal Impact Of Extending Market Exclusivity For Conventional Drugs." Health Affairs 30, no. 4 (April 2011): 798. http://dx.doi.org/10.1377/hlthaff.2011.0310.
Повний текст джерелаSocal, Mariana P., Sonal Parasrampuria, and Gerard F. Anderson. "Modifying the Criteria for Granting Orphan Drug Market Exclusivity." Value in Health 23, no. 11 (November 2020): 1470–76. http://dx.doi.org/10.1016/j.jval.2020.08.004.
Повний текст джерелаSinha, Michael S., Gregory D. Curfman, and Michael A. Carrier. "Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry." JAMA 319, no. 22 (June 12, 2018): 2271. http://dx.doi.org/10.1001/jama.2018.3478.
Повний текст джерелаApel, Brian. "An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act." Michigan Law Review, no. 114 (2015): 107. http://dx.doi.org/10.36644/mlr.114.1.administrative.
Повний текст джерелаChoi, Yong-Jae. "Exclusivity of Zero-rating Contracts in Competitive Internet Service Market." Information Society & Media 20, no. 2 (August 31, 2019): 101–22. http://dx.doi.org/10.52558/ism.2019.08.20.2.101.
Повний текст джерела’t Hoen, Ellen. "Protect against market exclusivity in the fight against COVID-19." Nature Medicine 26, no. 6 (May 7, 2020): 813. http://dx.doi.org/10.1038/s41591-020-0876-6.
Повний текст джерелаStorz, Ulrich. "Extending the market exclusivity of therapeutic antibodies through dosage patents." mAbs 8, no. 5 (April 26, 2016): 841–47. http://dx.doi.org/10.1080/19420862.2016.1180491.
Повний текст джерелаFisher, Dennis. "Do the Right Thing (or Do the Market Exclusivity Thing?)." Anesthesiology 105, no. 6 (December 1, 2006): 1074–75. http://dx.doi.org/10.1097/00000542-200612000-00003.
Повний текст джерелаBaker, Brook K. "Ending Drug Registration Apartheid: Taming Data Exclusivity and Patent/Registration Linkage." American Journal of Law & Medicine 34, no. 2-3 (June 2008): 303–44. http://dx.doi.org/10.1177/009885880803400209.
Повний текст джерелаLiang, Zhiwen. "Regulatory exclusivity protection for undisclosed test data in China: an innovative approach to implementing the TRIPS Agreement." Queen Mary Journal of Intellectual Property 10, no. 1 (February 19, 2020): 115–27. http://dx.doi.org/10.4337/qmjip.2020.01.05.
Повний текст джерелаGilchrist, Duncan S. "Patents as a Spur to Subsequent Innovation? Evidence from Pharmaceuticals." American Economic Journal: Applied Economics 8, no. 4 (October 1, 2016): 189–221. http://dx.doi.org/10.1257/app.20150373.
Повний текст джерелаHugenholtz, P. Bernt, and Joost Poort. "Film Financing in the Digital Single Market: Challenges to Territoriality." IIC - International Review of Intellectual Property and Competition Law 51, no. 2 (December 17, 2019): 167–86. http://dx.doi.org/10.1007/s40319-019-00900-2.
Повний текст джерелаGersten, Judge David M. "The quest for market exclusivity in biotechnology: Navigating the patent minefield." NeuroRX 2, no. 4 (October 2005): 572–78. http://dx.doi.org/10.1602/neurorx.2.4.572.
Повний текст джерелаGlover, Gregory J. "The influence of market exclusivity on drug availability and medical innovations." AAPS Journal 9, no. 3 (September 2007): E312—E316. http://dx.doi.org/10.1208/aapsj0903034.
Повний текст джерелаFernandez, Dennis S., and James T. Huie. "Balancing US patent and FDA approval processes: strategically optimizing market exclusivity." Drug Discovery Today 9, no. 12 (June 2004): 509–12. http://dx.doi.org/10.1016/s1359-6446(04)03067-3.
Повний текст джерелаKesselheim, Aaron S., Michael S. Sinha, and Jerry Avorn. "Determinants of Market Exclusivity for Prescription Drugs in the United States." JAMA Internal Medicine 177, no. 11 (November 1, 2017): 1658. http://dx.doi.org/10.1001/jamainternmed.2017.4329.
Повний текст джерелаPark, H., and T. Lee. "Market Exclusivity Periods And Patent Challenges In Pharmaceuticals In South Korea." Value in Health 19, no. 7 (November 2016): A444. http://dx.doi.org/10.1016/j.jval.2016.09.565.
Повний текст джерелаFeldman, William B., Doni Bloomfield, Reed F. Beall, and Aaron S. Kesselheim. "Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD." Nature Biotechnology 40, no. 9 (September 2022): 1319–25. http://dx.doi.org/10.1038/s41587-022-01451-7.
Повний текст джерелаMaxwell, Claire. "Distinction, exclusivity and whiteness. Elite Nigerian parents and the international education market." British Journal of Sociology of Education 41, no. 2 (January 23, 2020): 269–71. http://dx.doi.org/10.1080/01425692.2020.1715550.
Повний текст джерелаMiller, Chris P. "Increasing Market Exclusivity for New Drugs, the Cure for What Ails Us?" ACS Medicinal Chemistry Letters 3, no. 6 (May 16, 2012): 437–39. http://dx.doi.org/10.1021/ml300111p.
Повний текст джерелаWu, Wenxi, and Garth Stahl. "Distinction, exclusivity and whiteness: elite Nigerian parents and the international education market." Discourse: Studies in the Cultural Politics of Education 41, no. 3 (June 26, 2019): 497–500. http://dx.doi.org/10.1080/01596306.2019.1627756.
Повний текст джерелаHermalin, Benjamin E., and Michael L. Katz. "Product Differentiation through Exclusivity: Is there a One-Market-Power-Rent Theorem?" Journal of Economics & Management Strategy 22, no. 1 (January 9, 2013): 1–27. http://dx.doi.org/10.1111/jems.12008.
Повний текст джерелаKandel, M., A. Degrassat-Théas, O. Parent de Curzon, M. Sinègre, and P. Paubel. "Economic Impact of The End of The Market Exclusivity for Orphan Drugs." Value in Health 18, no. 7 (November 2015): A678. http://dx.doi.org/10.1016/j.jval.2015.09.2012.
Повний текст джерелаMAKSYMCHUK, Maksym. "INSTITUTIONAL BASIS OF EXCLUSIVITY OF REGIONAL DEVELOPMENT REGULATION." Ukrainian Journal of Applied Economics 5, no. 1 (March 1, 2020): 280–87. http://dx.doi.org/10.36887/2415-8453-2020-1-33.
Повний текст джерелаSon, Kyung-Bok. "Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States." Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector 14, no. 4 (September 6, 2018): 167–74. http://dx.doi.org/10.1177/1741134318799385.
Повний текст джерелаLee, Robin S. "Vertical Integration and Exclusivity in Platform and Two-Sided Markets." American Economic Review 103, no. 7 (December 1, 2013): 2960–3000. http://dx.doi.org/10.1257/aer.103.7.2960.
Повний текст джерелаNagar, Sarosh, and Aaron S. Kesselheim. "Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation." Journal of Law, Medicine & Ethics 49, no. 4 (2021): 683–87. http://dx.doi.org/10.1017/jme.2021.93.
Повний текст джерелаSarpatwari, Ameet, Reed F. Beall, Abdurrahman Abdurrob, Mengdong He, and Aaron S. Kesselheim. "Evaluating The Impact Of The Orphan Drug Act’s Seven-Year Market Exclusivity Period." Health Affairs 37, no. 5 (May 2018): 732–37. http://dx.doi.org/10.1377/hlthaff.2017.1179.
Повний текст джерелаKerr, Kirk W., and Lukas J. Glos. "Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases." Pharmaceutical Medicine 34, no. 1 (December 20, 2019): 19–29. http://dx.doi.org/10.1007/s40290-019-00317-9.
Повний текст джерелаStoate, Nigel. "EU enlargement, the Bolar exemption and parallel imports: The consequences for market exclusivity." Journal of Medical Marketing 3, no. 3 (June 1, 2003): 239–44. http://dx.doi.org/10.1057/palgrave.jmm.5040126.
Повний текст джерелаLexchin, Joel. "Market Exclusivity Time for Top Selling Originator Drugs in Canada: A Cohort Study." Value in Health 20, no. 8 (September 2017): 1139–42. http://dx.doi.org/10.1016/j.jval.2017.05.004.
Повний текст джерела